Project Grant HT9425261E479
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $956K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10027, USA
Similar Awards
- The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...
- The Defense Health Agency awarded The Rockefeller University $1.649998 million on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct therapeutic targeting of a commonly inherited breast cancer metastasis driver gene. Work performance is located in New York, NY with a period of performance through July 31, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded New York University School of Medicine $833,334 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify pathways that prevent the emergence of drug-tolerant persisters. The award supports basic and applied biomedical research with a period of performance through September 29, 2029, and work will be performed in New York, New York. The Military Medical Research and Development program funds R&D assistance...
- The Defense Health Agency awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $1,435,737 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify and evaluate immune and targeted therapies for acral melanoma. Work is performed in Tampa, Florida, with a period of performance extending through August 31, 2030. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
- The Defense Health Agency awarded The Trustees of Columbia University in the City of New York $1,099,932 on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support optimization of targeted drug delivery and radiosensitizing strategies for pediatric diffuse midline glioma. The project runs through May 31, 2030, with performance in New York, NY. The award funds basic and applied biomedical research intended to advance medical solutions and transform...
- The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, was awarded a $656,272 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research aimed at optimizing PD-1 immunotherapy through increased T cell regeneration and reduced antigen load. This 2-year project will be conducted in New York, NY from September 1, 2023 to August 31, 2025. The Military Medical...
- The Defense Health Agency awarded the Beckman Research Institute of the City of Hope $416,217 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop photoacoustic computed tomography technology for identifying and diagnosing axillary lymph nodes in breast cancer patients without surgery. Performance runs through September 29, 2029, at the Institute's Irwindale, California research facility. The Military Medical Research and Development program...
- The Defense Health Agency awarded the University of Pittsburgh $1,462,665 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate the intratumoral microbiome in acral melanoma. The three-year project runs through June 30, 2029, and is performed in Pittsburgh, Pennsylvania. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American...
- The Defense Health Agency awarded Icahn School of Medicine at Mount Sinai $1.25 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop first-in-class degraders targeting oncogenic PTK6 in triple negative breast cancer. The award is a project grant with a period of performance through April 30, 2029, and work is performed in New York, NY. The Military Medical Research and Development program supports basic, applied, and advanced biomedical...
- The Defense Health Agency awarded New York University School of Medicine $1.666 million on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify pathways that prevent the emergence of drug-tolerant persisters. The award supports basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative and impactful research. Work will be performed in New York, New York, with a...